BMP inhibition also resulted in reduced hepatic steatosis without altering glucose tolerance, which is consistent with previous studies which showed that manipulation of Dgat2 impacted hepatic steatosis without affecting glucose tolerance13,17,41. Here, DGAT2 is linked to fatty liver disease.